About Allcyte
Allcyte is a Healthcare company based in Vienna (Austria) founded in 2017, and was acquired by Exscientia in June 2021. Allcyte has raised $6 million across 2 funding rounds from investors including Exscientia, EIT Health and 42 Capital. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Formulation.
Company details
Developer of drugs for the treatment of cancer patients. It offers Pharmacoscopy high-content imaging platform that supports pre-clinical drug development and clinical decision making services. It enables research through the image-based quantification of single-cell phenotypes. It helps pharmaceutical companies to locate the most promising indications for their drug candidates, and doctors use it to find the correct drug for the right patients.
- Headquarters Vienna, Austria
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website allcyte.com
- Acquired by Exscientia (Jun 2021)
- Total Equity Funding$6M (USD)
in 2 rounds
- Latest Funding Round$6M (USD), Seed
Mar 2021
- InvestorsExscientia
& 6 more
- Acquired byExscientia
(Jun 2021)
Funding Insights of Allcyte
Allcyte has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $6 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6M
- Total Rounds 2
- Last Round Seed — $6M
- Investors Count 6
All 2 funding rounds of Allcyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $6M | Seed | – | 42 Capital, Air Street Capital | |
| Jul 2020 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Allcyte
Allcyte has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Exscientia, EIT Health and 42 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage technology companies are invested in across Europe. | 42cap.com | Munich, Germany | ||
Venture capital firm investing in AI & life science sectors | airstreet.com | St. Peter Port, United Kingdom | ||
Amino Collective is engaged in backing innovative startup founders. | aminocollective.com | |||
A Zurich-based VC firm focused on early-stage life science companies. | vpventurepartners.com | Zurich, Switzerland | ||
Healthcare startups are accelerated and incubated through specialized programs. | 2015 | eithealth.eu | Munich, Germany | |
Early-stage investments are made in green tech and healthcare startups by PUSH VC. | push.ventures | Vienna, Austria | ||
AI-driven drug discovery and precision medicine solutions are provided. | 2012 | exscientia.com | Oxford, United Kingdom |
Investor details for Allcyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Allcyte
4 dated milestones of Allcyte across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Allcyte is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $6.0M.
- Exit Acquired by Exscientia.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allcyte
Complete news archive for Allcyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allcyte
Allcyte was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Allcyte is headquartered in Vienna, Austria.
Allcyte is a funded company, having raised a total of $6M across 2 funding rounds to date.
Developer of drugs for the treatment of cancer patients. It offers Pharmacoscopy high-content imaging platform that supports pre-clinical drug development and clinical decision making services. It enables research through the image-based quantification of single-cell phenotypes. It helps pharmaceutical companies to locate the most promising indications for their drug candidates, and doctors use it to find the correct drug for the right patients.
Allcyte has 7 investors. Key investors include Exscientia, EIT Health, 42 Capital, Air Street Capital, and PUSH VC.
Yes. Allcyte was acquired by Exscientia in June 2021.